Is Kymera Therapeutics, Inc. (KYMR) a Buy, Sell, or Hold?
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$114.12 USD
$2.04 (1.82%)
- Volume
- 411.01K
- Average Volume
- 794.36K
- Market Capitalization
- $9.39B
- P/E Ratio
- -31.88
- Dividend Yield
- 0.00%
- Price Target
- $129.00
- Year High
- $130.05
- Year Low
- $36.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.81
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Nello Mainolfi |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KYMR |
| CUSIP | 501575104 |
| CIK | 0001815442 |
| Web | https://www.kymeratx.com |
| Phone | 857 285 5300 |
| Currency | USD |
| Employees | 253 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.81 |
| Quick Ratio | 10.81 |
| Cash Ratio | 2.30 |
Sales & Book Value
| Annual Sales | $39.2M |
| Price / Sales | 182.40 |
| Cash Flow | -2.50 |
| Price / Cash Flow | -38.47 |
| Price / Book | 7.23 |
Price Target and Rating
| Average Stock Price Forecast | $129.00 |
| High Stock Price Forecast | $155.00 |
| Low Stock Price Forecast | $97.00 |
| Forecast Upside/Downside | -11.53% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 27 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.69 |
| Trailing P/E Ratio | -31.88 |
| PEG Ratio | 2.14 |
| P/E Growth | 2.14 |
| Net Income | $-311.4M |
| Net Margin | -612.17% |
| Pretax Margin | -612.60% |
| Return on Equity | -25.02% |
| Return on Assets | -18.88% |
Financials Score
| AltmanZ Score | 42.43 |
| Piotroski Score | 2.00 |
| Working Capital | 614.79M |
| Total Assets | 1.67B |
| Ebit | -315.04M |
| Market Cap | 9.39B |
| Total Liabilities | 129.38M |
Poll Results
About Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, soli ... d tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Kymera's CEO Sold $6 Million in Stock After a 170% Run
2026-07-12 16:37:46
According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock holdings by 7%, leaving a residual direct position of 667,000 shares.
2026-07-07 07:00:00
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass.
2026-07-07 07:00:00
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Elizabeth Laws, Ph.D.
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
2026-07-03 10:44:38
Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5bn cash position. KT-621, an oral STAT6 degrader for atopic dermatitis, has accelerated Phase 2b timelines with topline data now expected by year-end 2026. KT-621's oral administration and promising early efficacy/safety data position KYMR to challenge injectable incumbents in a multi-billion dollar market.
Kymera: Building Toward A Defining 2H26 Moment
2026-07-03 05:24:14
Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection point. KT-621, a first-in-class oral STAT6 degrader, targets large, expanding markets in atopic dermatitis and other type 2 inflammatory diseases. Rapid trial enrollment, a strong balance sheet ($1.55B cash), and external validation position KYMR for potential high-value partnerships and lifecycle expansion.
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
2026-07-01 14:11:08
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Why Kymera Therapeutics Stock Popped This Week
2026-06-26 18:45:57
It completed the enrollment phase of a Phase 2b study of its leading drug candidate. This medication will be trialed to gauge its efficacy in treating severe atopic dermatitis.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
2026-06-26 11:30:20
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
Frequently Asked Questions
-
What is the current Kymera Therapeutics, Inc. (KYMR) stock price?
-
Kymera Therapeutics, Inc.(NASDAQ:KYMR) stock price is $114.12 in the last trading session. During the trading session, KYMR stock reached the peak price of $130.05 while $36.65 was the lowest point it dropped to. The percentage change in KYMR stock occurred in the recent session was 1.82% while the dollar amount for the price change in KYMR stock was $2.04.
-
KYMR's industry and sector of operation?
-
The NASDAQ listed KYMR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KYMR?
-
Jeremy G. Chadwick | Advisor
Bruce L. Booth DPHIL | Co-Founder & Independent Chairman
Neil Graham MBBS | Chief Development Officer
Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director
Brian Albarran | SVP of Corporate Strategy -
How many employees does KYMR have?
-
Number of KYMR employees currently stands at 253. KYMR operates from 200 Arsenal Yards Boulevard, Watertown, MA 02472, US.
-
Link for KYMR official website?
-
Official Website of KYMR is: https://www.kymeratx.com
-
How do I contact KYMR?
-
KYMR could be contacted at phone #857 285 5300 and can also be accessed through its website. KYMR operates from 200 Arsenal Yards Boulevard, Watertown, MA 02472, US.
-
How many shares of KYMR are traded daily?
-
The average number of KYMR shares traded daily for last 3 months was 794.36K.
-
What is the market cap of KYMR currently?
-
The market value of KYMR currently stands at $9.39B with its latest stock price at $114.12